Metraipolis › archive › dc_1ea2c76ca8bb

Telitacicept versus belimumab in proliferative lupus nephritis — Europe PMC PMID:41635846

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41635846
DOI: 10.3389/fimmu.2025.1715593
License (as archived): solo-consultazione
Archived: 2026-11-06T16:57:38.021Z
SHA-256 of the archived text: d36a93a4c44ea57a1e455bd9732e6b55c2977ecbff91a6835cabdf2cba8c5925
Stable URL of this page: https://metraipolis.com/documento/dc_1ea2c76ca8bb

How to cite

Telitacicept versus belimumab in proliferative lupus nephritis — Europe PMC PMID:41635846 — Europe PMC (en), https://europepmc.org/article/MED/41635846 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1ea2c76ca8bb (Metraipolis archive dc_1ea2c76ca8bb, sha256 d36a93a4c44ea57a1e455bd9732e6b55c2977ecbff91a6835cabdf2cba8c5925)

BibTeX

@misc{dc1ea2c76ca8bb,
  title = {Telitacicept versus belimumab in proliferative lupus nephritis — Europe PMC PMID:41635846},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41635846},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1ea2c76ca8bb; sha256 d36a93a4c44ea57a1e455bd9732e6b55c2977ecbff91a6835cabdf2cba8c5925},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41635846. Agents can read the archived copy with the MCP tool read_document.